| P50 | author | Thiravat Hemachudha | Q13015868 |
| | Ivana Knezevic | Q79361621 |
| P2093 | author name string | Lea Knopf | |
| | Deborah Briggs | |
| | Martine Denis | |
| | Henry Wilde | |
| P2860 | cites work | One clinic visit for pre-exposure rabies vaccination (a preliminary one year study). | Q50520532 |
| | A 4‐Site, Single‐Visit Intradermal Postexposure Prophylaxis Regimen for Previously Vaccinated Patients: Experiences with >5000 Patients | Q50559311 |
| | Postexposure rabies prophylaxis completed in 1 week: preliminary study. | Q50590850 |
| | Failure of rabies postexposure prophylaxis in patients presenting with unusual manifestations. | Q50590856 |
| | Comparison of saftey and immunogenicity of purified chick embryo cell rabies vaccine (PCECV) and purified vero cell rabies vaccine (PVRV) using the Thai Red Cross intradermal regimen at a dose of 0.1 ML. | Q50718492 |
| | Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen. | Q50739641 |
| | Potency requirements of rabies vaccines administered intradermally using the Thai Red Cross regimen: investigation of the immunogenicity of serially diluted purified chick embryo cell rabies vaccine. | Q50765276 |
| | Postexposure prophylaxis for rabies with antiserum and intradermal vaccination | Q68085914 |
| | Immunogenicity of rabies postexposure booster injections in subjects who had previously received intradermal preexposure vaccination | Q73212501 |
| | Potency, sterility and immunogenicity of rabies tissue culture vaccine after reconstitution and refrigerated storage for 1 week | Q74092635 |
| | Four-site intradermal postexposure boosters in previously rabies vaccinated subjects | Q74378846 |
| | Prospective immunogenicity study of multiple intradermal injections of rabies vaccine in an effort to obtain an early immune response without the use of immunoglobulin | Q78627230 |
| | Antigen content versus volume of rabies vaccines administered intradermally | Q82033047 |
| | Equivalence between pre-exposure schemes for human rabies and evaluation of the need for serological monitoring | Q84212077 |
| | Safety and efficacy of novel dermal and epidermal microneedle delivery systems for rabies vaccination in healthy adults | Q84520496 |
| | The importance of rabies immunoglobulin in postexposure prophylaxis | Q86725837 |
| | 30 Years of rabies vaccination with Rabipur: a summary of clinical data and global experience | Q30893254 |
| | Rabies post-exposure prophylaxis in the Philippines: health status of patients having received purified equine F(ab')(2) fragment rabies immunoglobulin (Favirab). | Q33338456 |
| | Paralytic rabies following cat scratch and intra-dermal anti-rabies vaccination | Q34201487 |
| | Safety and immunogenicity study of a new purified chick embryo cell rabies vaccine Vaxirab-N (Pitman-Moore strain) manufactured in India | Q34271554 |
| | Assessing the relationship between antigenicity and immunogenicity of human rabies vaccines when administered by intradermal route: results of a metaanalysis | Q35878615 |
| | Comparison of safety and immunogenicity of 2 WHO prequalified rabies vaccines administered by one week, 4 site intra dermal regimen (4-4-4-0-0) in animal bite cases | Q35896228 |
| | Reducing Cost of Rabies Post Exposure Prophylaxis: Experience of a Tertiary Care Hospital in Pakistan | Q35937492 |
| | A simplified 4-site economical intradermal post-exposure rabies vaccine regimen: a randomised controlled comparison with standard methods | Q36538027 |
| | Evaluation of a one week intradermal regimen for rabies post-exposure prophylaxis: results of a randomized, open label, active-controlled trial in healthy adult volunteers in India | Q36552888 |
| | Assessing safety and immunogenicity of post-exposure prophylaxis following interchangeability of rabies vaccines in humans | Q36977600 |
| | Safety and Immunogenicity of purified chick embryo cell rabies vaccine (VaxiRab N) administered intradermally as post exposure prophylaxis | Q36978461 |
| | Preventing rabies with the Verorab vaccine: 1985-2005 Twenty years of clinical experience | Q36993795 |
| | Local infiltration of rabies immunoglobulins without systemic intramuscular administration: An alternative cost effective approach for passive immunization against rabies | Q37135159 |
| | Evaluation of a new five-injection, two-site,intradermal schedule for purified chick embryo cell rabies vaccine: A randomized, open-label, active-controlled trial in healthy adult volunteers in India | Q37660987 |
| | Rabies in South Asia: fighting for elimination. | Q39019771 |
| | A three-year clinical study on immunogenicity, safety, and booster response of purified chick embryo cell rabies vaccine administered intramuscularly or intradermally to 12- to 18-month-old Thai children, concomitantly with Japanese encephalitis vac | Q39348156 |
| | Rabies post-exposure prophylaxis with purified equine rabies immunoglobulin: one-year follow-up of patients with laboratory-confirmed category III rabies exposure in the Philippines | Q39374912 |
| | Reducing the cost of post-exposure rabies prophylaxis: efficacy of 0.1 ml PCEC rabies vaccine administered intradermally using the Thai Red Cross post-exposure regimen in patients severely exposed to laboratory-confirmed rabid animals | Q39374941 |
| | NIH test, a problematic method for testing potency of inactivated rabies vaccine | Q39616689 |
| | A single center, open label study of intradermal administration of an inactivated purified chick embryo cell culture rabies virus vaccine in adults | Q40130867 |
| | Injecting rabies immunoglobulin (RIG) into wounds only: A significant saving of lives and costly RIG. | Q40300404 |
| | Immunogenicity and safety study of Indirab: a Vero cell based chromatographically purified human rabies vaccine | Q40360937 |
| | Rabies Vaccine and Rabies Immunoglobulin in Cambodia: Use and Obstacles to Use. | Q41588040 |
| | Single visit rabies pre-exposure priming induces a robust anamnestic antibody response after simulated post-exposure vaccination: results of a dose-finding study | Q41933630 |
| | Safety and immunogenicity of chromatographically purified Vero cell rabies vaccine for intradermal pre- and post-exposure rabies prophylaxis | Q42183661 |
| | Economical multi-site intradermal regimen with purified chick embryo cell vaccine (Rabipur) prevents rabies in people bitten by confirmed rabid animals | Q43584586 |
| | A preliminary study of chemo- and cytokine responses in rabies vaccine recipients of intradermal and intramuscular regimens | Q43772717 |
| | A pilot study on intradermal vaccination of Japanese rabies vaccine for pre-exposure immunization | Q43858103 |
| | Revision of the Thai Red Cross intradermal rabies post-exposure regimen by eliminating the 90-day booster injection | Q44703180 |
| | Immunogenicity and safety of low-dose intradermal rabies vaccination given during an Expanded Programme on immunization session in Viet Nam: results of a comparative randomized trial | Q44763423 |
| | Immunogenicity of intradermal vaccination of Japanese rabies vaccine for preexposure immunization following WHO recommendation | Q44899552 |
| | Antibody response to an eight-site intradermal rabies vaccination in patients infected with Human Immunodeficiency Virus | Q45383983 |
| | Failure of multiple-site intradermal postexposure rabies vaccination in patients with human immunodeficiency virus with low CD4+ T lymphocyte counts | Q45735194 |
| | Safety and immunogenicity of a new purified vero cell rabies vaccine (PVRV) administered by intramuscular and intradermal routes in healthy volunteers | Q46335060 |
| | Simulated post-exposure rabies vaccination with purified chick embryo cell vaccine using a modified Thai Red Cross regimen | Q47698810 |
| | Paralytic rabies or postvaccination myelitis: a diagnostic dilemma | Q47781753 |
| | A randomized non-inferiority clinical study to assess post-exposure prophylaxis by a new purified vero cell rabies vaccine (Rabivax-S) administered by intramuscular and intradermal routes | Q47954549 |
| | Rabies neutralizing antibody after 2 intradermal doses on days 0 and 21 for pre-exposure prophylaxis. | Q50495857 |
| P921 | main subject | rabies | Q39222 |
| | rabies vaccine | Q4007169 |
| P304 | page(s) | A99-A106 | |
| P577 | publication date | 2018-12-11 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | An overview of the immunogenicity and effectiveness of current human rabies vaccines administered by intradermal route | |
| P478 | volume | 37 Suppl 1 | |